Foto del docente

Andrea Ardizzoni

Professore ordinario

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Settore scientifico disciplinare: MED/06 ONCOLOGIA MEDICA

Pubblicazioni

De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A., Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach, «EUROPEAN JOURNAL OF CANCER», 2021, 143, pp. 75 - 77 [articolo]

Mollica, Veronica; Franceschini, Tania; Gruppioni, Elisa; Rizzo, Alessandro; Ricci, Costantino; Schiavina, Riccardo; Brunocilla, Eugenio; Ardizzoni, Andrea; Fiorentino, Michelangelo; Giunchi, Francesca; Massari, Francesco, Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 219, pp. 1 - 7 [articolo]

Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [articolo]

Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna, IFN-γ and CD38 in Hyperprogressive Cancer Development, «CANCERS», 2021, 13, pp. 1 - 24 [articolo]Open Access

Comito F.; Nigro M.C.; Sperandi F.; Melotti B.; Ardizzoni A., Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab, «EUROPEAN JOURNAL OF CANCER», 2021, 146, pp. 84 - 86 [articolo]

Rizzo A.; Mollica V.; Giunchi F.; Dall'Olio F.G.; Rosellini M.; Marchetti A.; Franceschini T.; Schiavina R.; Brunocilla E.; Fiorentino M.; Ardizzoni A.; Massari F., Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 220, pp. 1 - 5 [articolo]

Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, pp. 1 - 13 [articolo]

Mollica, Veronica; Rizzo, Alessandro; Tassinari, Elisa; Giunchi, Francesca; Schiavina, Riccardo; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study, «ANTI-CANCER DRUGS», 2021, 32, pp. 74 - 81 [articolo]

Francesca Coppola, Margherita Mottola, Silvia Lo Monaco, Arrigo Cattabriga, Maria Adriana Cocozza, Jia Cheng Yuan, Caterina De Benedittis, Dajana Cuicchi, Alessandra Guido, Fabiola Lorena Rojas Llimpe, Antonietta D’Errico, Andrea Ardizzoni, Gilberto Poggioli, Lidia Strigari, Alessio Giuseppe Morganti, Franco Bazzoli, Luigi Ricciardiello, Rita Golfieri, Alessandro Bevilacqua, The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer, «DIAGNOSTICS», 2021, 11, pp. 1 - 13 [articolo]

Massucci, Maria; Di Fabio, Francesca; Rojas Llimpe, Fabiola L; Ardizzoni, Andrea, A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease in Steroid Therapy, «JOURNAL OF IMMUNOTHERAPY», 2020, 43, pp. 153 - 155 [articolo]

Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [articolo]

Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [articolo]Open Access

Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A., Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2020, 156, pp. 1 - 18 [articolo]

Dall'Olio F.G.; Abbati F.; Facchinetti F.; Massucci M.; Melotti B.; Squadrilli A.; Buti S.; Formica F.; Tiseo M.; Ardizzoni A., CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 4 [articolo]Open Access

Felip E.; Ardizzoni A.; Ciuleanu T.; Cobo M.; Laktionov K.; Szilasi M.; Califano R.; Carcereny E.; Griffiths R.; Paz-Ares L.; Duchnowska R.; Garcia M.A.; Isla D.; Jassem J.; Appel W.; Milanowski J.; Van Meerbeeck J.P.; Wolf J.; Li A.; Acevedo A.; Popat S., CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations, «EUROPEAN JOURNAL OF CANCER», 2020, 127, pp. 160 - 172 [articolo]